This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
15 Dec 2011

Eisai Submits Aricept Application in Japan

Eisai has submitted a marketing and manufacturing authorisation application in Japan to seek approval of a new dry syrup formulation of Aricept.

Eisai has submitted a marketing and manufacturing authorisation application in Japan to seek approval of a new dry syrup formulation of its Alzheimer's disease treatment Aricept (donepezil hydrochloride).

 

In August 2007, the indication of Aricept was expanded to include severe Alzheimer’s disease. The simultaneous approval of additional daily dosage to a maximum of 10mg also made it possible to adjust Aricept dosage amounts.

 

This latest version of Aricept is a dry syrup formulation that can be administered by suspending dry syrup powder with water, which allows dosage to be adjusted within approved dosage amounts at the time of administration depending on the needs of individual patients. It was designed as a suspension to make it easier for patients who find powder t

Related News